Azienda Ospedaliero Universitaria Pisana Trials

Azienda Ospedaliero Universitaria Pisana	Welcome, Profile Billing Logout

1438 Trials

Active Trials

12 3 4 5 6 7 8 9 10 11 12 13...14 15 »

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Heinemann, Volker

FIRE-4, NCT02934529 / 2014-003787-21: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Completed

673

Europe

Irinotecan, Campto, Folinic Acid, Folgamma mono, 5-FU, Fluorouracil, Cetuximab, Erbitux, Bevacizumab, Avastin, Capecitabine, Xeloda, regorafenib, CAS #:755037-03-7, Irinotecan 125mg, Cetuximab wkly

Ludwig-Maximilians - University of Munich

Metastatic Colorectal Cancer

01/25

RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed

430

Europe

Ramucirumab, TAS 102

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH

Colorectal Cancer

07/24

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Colorectal Neoplasms

04/26

07/29

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

FOOTPATH, NCT03487016: First-line Therapy in Metastatic PDAC

Active, not recruiting

270

Europe

Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, 5-FU, 5-Fluoruracil, Irinotecan Liposomal Injection, Onivyde, Oxaliplatin, Trans-l-diaminocyclohexanoxalatoplatin

Ludwig-Maximilians - University of Munich

Metastatic Pancreatic Cancer

07/22

07/23

FIRE-4.5, NCT04034459: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

Active, not recruiting

109

Europe

Bevacizumab, Irinotecan, Folinic acid, Oxaliplatin, 5-FU, Cetuximab

Ludwig-Maximilians - University of Munich

Metastatic Colorectal Cancer

11/23

12/23

NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Completed

124

Europe

Aflibercept + mLV5FU2, mFOLFOX7

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi

Colorectal Cancer

02/24

NCT04034173: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Not yet recruiting

120

Europe

Panitumumab, Irinotecan, Folinic acid, 5-FU

Ludwig-Maximilians - University of Munich, Amgen, ClinAssess GmbH

Treatment Related Cancer

08/24

08/26

AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting

154

Europe, Canada, Japan, US, RoW

Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A

GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd

Neoplasms, Rectal

11/26

10/29

C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Completed

1/2

Europe, US

MEN1611, Cetuximab

Menarini Group, Menarini Ricerche S.p.A.

Metastatic Colorectal Cancer

01/24

02/24

TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting

N/A

500

Europe, RoW

Data collection and quality of life questionnaire

Centre Leon Berard

Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation

06/25

FIRE-7, NCT04852250: Centralized Tumour Board and Secondary Intervention Rate in mCRC

Not yet recruiting

N/A

130

Virtual centralized multidisciplinary tumour board

Ludwig-Maximilians - University of Munich, Charité Universitätsmedizin, Department of Hematology, Oncology and Tumor Immunology

Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication, Secondary Intervention

03/23

03/25

Ryoo, Baek-Yeol

ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting

2/3

600

Europe, US, RoW

SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo

Panbela Therapeutics, Inc.

Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

08/26

01/27

Petronio, Anna S

GIOTTO, NCT03521921: GIse Registry Of Transcatheter Treatment of Mitral Valve regurgitaTiOn

Active, not recruiting

N/A

1500

Europe

Mitraclip

IRCCS Policlinico S. Donato

Mitral Regurgitation

02/21

09/25

AHEAD, NCT03339115: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System

Recruiting

N/A

Europe

Cardiovalve Transfemoral Mitral Valve

Cardiovalve Ltd., Meditrial Europe Ltd., Meditrial SrL

Mitral Regurgitation, Mitral Valve Disease

12/24

12/29

NCT04817735: The CASPER Registry

Completed

N/A

100

Europe

TAVI

University of Pisa

Bicuspid Aortic Valve

12/24

RESOLVE-MR, NCT04818502: Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Active, not recruiting

N/A

200

Europe, RoW

Tendyne™ Mitral Valve System, Transcatheter Mitral Valve Implantation (TMVI)

Abbott Medical Devices

Mitral Valve Regurgitation

05/25

05/29

TENDER, NCT04898335: Tendyne European Experience Registry

Recruiting

N/A

400

Europe

Tendyne Mitral Valve System

Klinikum der Universitaet Muenchen

Mitral Regurgitation

12/26

12/27

Caterina, Raffaele De

RISE-HF, NCT06270498: Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure

Recruiting

Europe

Sucrosomial iron, SiderAL Forte, Placebo

Raffaele De Caterina, University of Pisa, Italy

Chronic Heart Failure, Iron-deficiency, Left Ventricular Systolic Dysfunction

03/25

06/25

CAMP, NCT04679727: The Carotid Artery Multi-modality Imaging Prognostic () Study

Recruiting

N/A

200

Europe

Azienda Ospedaliero, Universitaria Pisana, University of Florence, Azienda USL Toscana Nord Ovest, Fondazione Toscana Gabriele Monasterio, Lund University Hospital, University Medical Center Groningen

Carotid Artery Diseases, Carotid Artery Plaque, Carotid Atherosclerosis

07/23

07/24

BORG, Christophe

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting

920

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

PHARBEVACOL, NCT06642844: Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Not yet recruiting

244

Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group

University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy

Unresectable Metastatic Colorectal Cancer

10/28

10/29

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Colorectal Neoplasms

04/26

07/29

SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting

800

Europe

Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine

UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament

Biliary Tract Neoplasms

06/27

06/28

REPROGRAM-02, NCT05462613: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Recruiting

2/3

446

Europe

quality of life questionnaires, Blood sample, Regorafenib, Metronomic chemotherapies, Aspirin, Bevacizumab, FOLFIRI or FOLFOX

Centre Hospitalier Universitaire de Besancon

Metastatic Colorectal Cancer

11/29

11/30

APACaPOp, NCT03400072: Adapted Physical Activity in Patients With Resected Pancreatic Cancer ( PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial

Recruiting

252

Europe

Unsupervised APA program, Supervised APA program

Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group

Pancreas Cancer, Quality of Life

02/22

08/24

IMMUNO-BIL, NCT03704480: Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Active, not recruiting

106

Europe

Durvalumab, MEDI4736, Tremelimumab, CP-675

GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca

Advanced Biliary Tract Carcinoma

07/22

12/24

SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting

Europe

MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil

GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG

Anal Cancer

02/23

12/24

DONEPEZOX, NCT05254639: Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study

Completed

Europe

DONEPEZIL, PLACEBO

University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive

Digestive Oncology, Supportive Care

01/24

MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting

307

Europe

Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan

GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca

Metastatic Pancreatic Adenocarcinoma

07/23

12/24

SPARTANA, NCT04894370: Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

Recruiting

Europe

Sample collection

Centre Hospitalier Universitaire de Besancon, National Cancer Institute, France, Novartis

Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma

06/25

11/26

KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting

352

Europe, Canada, US

tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin

Seagen, a wholly owned subsidiary of Pfizer, Genmab, Merck Sharp & Dohme LLC

Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck

09/25

08/26

CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

Terminated

Europe

FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine

Centre Hospitalier Universitaire de Besancon

Metastatic Colorectal Cancer

08/24

11/24

TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting

106

Europe

FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi

GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics

Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer

12/23

12/24

C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting

234

Europe, US, RoW

Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care

Agenus Inc.

Metastatic Colorectal Cancer

02/25

07/25

ALIX, NCT03974854: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma

Terminated

Europe

XELOXIRI-3, Capecitabine, Oxaliplatine, Irinotecan, Gemcitabine

Centre Hospitalier Universitaire de Besancon

Metastatic Pancreatic Adenocarcinoma

08/23

02/24

INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.

Active, not recruiting

Europe

Blood sample collection, Biopsy

Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim

Squamous Cell Carcinoma of the Anus Stage III

11/24

07/26

CARE, NCT06425133: Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

Recruiting

174

Europe

Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy

Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation

Metastatic Colorectal Cancer

09/27

09/28

VolATIL, NCT03946358: Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers

Completed

Europe

Blood sample collection, Tumor biopsies, CT scan, Atezolizumab, anti-PD-L1, UCPVax, Vaccine

Centre Hospitalier Universitaire de Besancon, Roche Pharma AG, National Cancer Institute, France

Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer

03/24

11/24

REGINA, NCT04503694 / 2020-000876-40: Neoadjuvant Regorafenib in Combination with Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Recruiting

Europe

Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy, Surgery, Non-operative Management

Jules Bordet Institute

Rectal Cancer Stage II, Rectal Cancer Stage III

01/26

12/30

FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Recruiting

400

Europe

FOLFOX regimen, CAPOX regimen

UNICANCER

Digestive Cancer, Colorectal Cancer

04/27

01/30

TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Not yet recruiting

Europe

Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab

UNICANCER, Servier

Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency

10/26

10/28

TERTIO, NCT05528952: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting

105

Europe

Atezolizumab, Bevacizumab, UCPVax

Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE

Hepatocellular Carcinoma

04/25

09/27

LOGICAN, NCT05476796 / 2022-000273-81: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting

118

Europe

Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO

UNICANCER, Servier

Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

01/26

01/27

NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting

Europe

Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen

Inspirna, Inc.

Colorectal Cancer, Metastatic Colon Cancer

01/25

03/25

AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting

154

Europe, Canada, Japan, US, RoW

Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A

GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd

Neoplasms, Rectal

11/26

10/29

NIPISAFE, NCT04730544 / 2020-004366-19: Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

Active, not recruiting

Europe

Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab

GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb

Colorectal Cancer Metastatic, MSI-H Colorectal Cancer

04/27

04/28

TASKIN, NCT05201352: Evaluation of Efficacy of Trifluridine/Tipiracil Plus an Anti-IL-1α True Human Antibody Versus Trifluridine/Tipiracil Plus Placebo in Metastatic Colorectal Cancer Patients After Failure of Oxaliplatin, Irinotecan, Fluoropyrimidine

Recruiting

1/2

160

Europe

trifluridine/tipiracil + XB2001, trifluridine/tipiracil + placebo

Centre Georges Francois Leclerc

Metastatic Colorectal Cancer

10/26

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

374

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

01/26

AUDREY, NCT05589597 / 2022-002805-90: EO4010 in Previously Treated Metastatic Colorectal Carcinoma

Active, not recruiting

1/2

Europe, US

EO4010, Nivolumab, Bevacizumab

Enterome, Enterome SA

Colorectal Cancer Metastatic

02/26

Epitopes-CRC01, NCT02838381: Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer

Completed

N/A

553

Europe

Additional biological samples

Centre Hospitalier Universitaire de Besancon

Metastatic Cancer

12/23

06/24

PREDICT-IRFC, NCT04767568: Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening

Recruiting

N/A

400

Europe

Blood sample, Tumor tissue, stool collection

Centre Hospitalier Universitaire de Besancon

Colorectal Cancer

08/25

09/28

Pancreas-CGE, NCT02818907: Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

Completed

N/A

290

Europe

Additional biological samples

Centre Hospitalier Universitaire de Besancon, Cancéropôle Grand-Est

Pancreatic Cancer

07/23

NCT06515821: Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods

Recruiting

N/A

4100

Europe, RoW

ONCOSCREEN

Firalis SA, University Medical Center Mainz

Colorectal Cancer

12/26

HORIZON, NCT06626269: Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies

Not yet recruiting

N/A

700

Europe

Blood sample, Tumor tissue

Centre Hospitalier Universitaire de Besancon

Advanced Digestive Cancer, Advanced Gynecologic Cancer

01/30

01/32

CLIMES, NCT05787197: ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

Recruiting

N/A

232

Europe

GERCOR - Multidisciplinary Oncology Cooperative Group

Metastatic Colorectal Cancer, Circulating Tumor DNA

09/25

06/27

CIRCA-HPV, NCT03739775: Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

Recruiting

N/A

172

Europe

Blood sampling

Institut Curie

HPV Positive Pelvic Cancer

06/26

SMITH, Denis

COMPOSE, NCT04919226 / 2021-001086-20: Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) -

Recruiting

250

Europe, US, RoW

177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, 177Lu-DOTATOC 177Lu-Edo, CAPTEM (Capecitabine and Temozolomide), Amino-Acid Solution, Arginine-Lysine Solution, Everolimus, FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)

ITM Solucin GmbH

Neuroendocrine Tumors

06/27

09/27

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Colorectal Neoplasms

04/26

07/29

OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting

348

Europe

Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI

Federation Francophone de Cancerologie Digestive

Colorectal Neoplasms

09/25

09/27

AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting

Europe

MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil

GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG

Anal Cancer

02/23

12/24

DONEPEZOX, NCT05254639: Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study

Completed

Europe

DONEPEZIL, PLACEBO

University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive

Digestive Oncology, Supportive Care

01/24

NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients with NET

Completed

Europe, US

Surufatinib, HMPL-012, sulfatinib

Hutchmed

Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET

10/24

IMMUNOGAST, NCT04739202 / 2020-000297-17: Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma

Recruiting

Europe

Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab

Hospices Civils de Lyon, Roche, Inca

Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma

10/23

LONGBOARD, NCT04166604: LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy

Active, not recruiting

176

Europe

Trifluridine/Tipiracil, Lonsurf

GERCOR - Multidisciplinary Oncology Cooperative Group

Metastatic Colorectal Cancer

11/23

11/24

Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI

Recruiting

120

Europe

Dostarlimab, Chemotherapy

UNICANCER, National Cancer Institute, France, GlaxoSmithKline

Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma

10/28

09/30

POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting

Europe

Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab

Federation Francophone de Cancerologie Digestive

Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable

09/24

SOREGATT, NCT04450836 / 2019-004196-39: Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

Terminated

234

Europe

Regorafenib then Trifluridine/Tipiracil, STIVARGA, LONSURF, Trifluridine/Tipiracil then Regorafenib

UNICANCER, Bayer HealthCare Pharmaceuticals Inc.

Metastatic Colorectal Cancer

03/24

12/24

FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Recruiting

400

Europe

FOLFOX regimen, CAPOX regimen

UNICANCER

Digestive Cancer, Colorectal Cancer

04/27

01/30

AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting

154

Europe, Canada, Japan, US, RoW

Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A

GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd

Neoplasms, Rectal

11/26

10/29

NIPISAFE, NCT04730544 / 2020-004366-19: Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

Active, not recruiting

Europe

Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab

GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb

Colorectal Cancer Metastatic, MSI-H Colorectal Cancer

04/27

04/28

BETTER 2, NCT03351296 / 2017-000741-46: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting

140

Europe

LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab

Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France

Pancreatic Cancer

12/28

NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting

Europe

Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment

GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD

Neuroendocrine Carcinoma, Digestive Cancer

01/34

06/34

CLIMES, NCT05787197: ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

Recruiting

N/A

232

Europe

GERCOR - Multidisciplinary Oncology Cooperative Group

Metastatic Colorectal Cancer, Circulating Tumor DNA

09/25

06/27

Petrini, Mario

TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL

Recruiting

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

GITMO-PHYLOS, NCT03270748: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

Completed

Europe

GvHD prophylaxis

Gruppo Italiano Trapianto di Midollo Osseo

Myeloid Malignancies

11/22

NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting

Europe

Ibrutinib, IMBRUVICA (commercial name)

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

DLBCL

07/24

07/27

FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated

Europe

Copanlisib, ALIQOPA

Fondazione Italiana Linfomi - ETS

Diffuse Large B-cell Lymphoma

12/24

Simoncini, Tommaso

NCT04209543 / 2019-001289-14: Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Completed

1570

Europe, Canada, US, RoW

Estetrol, Placebo, Progesterone

Estetra, ICON Clinical Research

Vasomotor Symptoms, Menopausal Symptoms

02/24

MoMM-FET, NCT06288126: Maternal and Fetal Metabolic Changes

Completed

N/A

457

Europe

Azienda Ospedaliero, Universitaria Pisana

Pregnancy Related, Maternal-Fetal Relations, Metabolism Disorder, Glucose

10/20

01/21

MATERNALLY, NCT06852703: Predictive BioMArkers of AlTERed NeurologicAL Trajectories Consequent to PrenataL InflammatorY Insults

Recruiting

N/A

300

Europe

Infection during pregnancy

Istituto Clinico Humanitas, IRCCS Fondazione Stella Maris, Azienda Ospedaliero, Universitaria Pisana

Biomarkers, Neurodevelopmental Disorders, Inflammation, Brain

04/24

08/25

Investigator, Principal

OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Completed

144

Europe

Opicapone 50 mg, BIA 9-1067, Placebo

Bial - Portela C S.A., Bial - Portela & Ca, S.A.

Parkinson Disease

02/24

NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting

100

Ketamine

University of Oklahoma

Hemorrhoids

01/25

07/25

NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed

140

RoW

Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox

Daiichi Sankyo

COPD Exacerbation Acute

09/24

TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct

Recruiting

150

RoW

Rifaximin 550 MG, Azithromycin 500 MG, Loperamide

Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences

Diarrhoea;Acute, Diarrhea Travelers

09/25

12/25

NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Recruiting

TARPEYO®, delayed-release budesonide capsules

Calliditas Therapeutics AB, Worldwide Clinical Trials

IgA Nephropathy

05/26

11/27

NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

Not yet recruiting

fentanyl and Remimazolam

Indiana University, Indiana University Health

Dental Extraction

03/26

POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Terminated

109

Tamsulosin Hydrochloride

University of Massachusetts, Worcester, UMass Memorial Health Care

Thoracic Diseases, Urinary Retention

10/23

NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Not yet recruiting

100

Skin Cleanser Combination No.1

Boston Children's Hospital

Atopic Dermatitis

12/28

NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting

165

Europe, Canada, US, RoW

Macitentan, ACT-064992, Standard-of-care

Actelion

Pulmonary Arterial Hypertension

08/24

11/25

TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

	Oct 2024 - Mar 2025 : Regulatory decision in US for 2L+ NSCLC
	Jul 2023 - Dec 2023 : Acceptance of regulatory submission for 2L+ NSCLC with or without actionable genomic alterations (based on TROPION-Lung01 trial)
	Apr 2023 - Jun 2023: Topline results from TROPION-LUNG01 trial for metastatic NSCLC

Active, not recruiting

590

Europe, Canada, Japan, US, RoW

DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel

Daiichi Sankyo, AstraZeneca

Non-small Cell Lung Cancer

05/24

01/26

IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting

540

Europe, Canada, Japan, US, RoW

Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin

Daiichi Sankyo, Merck Sharp & Dohme LLC

Small Cell Lung Cancer

04/27

02/29

TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting

632

RoW

docetaxel, nedaplatin, and capecitabine, TNX induction chemotherapy, nedaplatin, N, docetaxel, cisplatin, and fluorouracil, TPF induction chemotherapy, cisplatin, P, docetaxel, cisplatin, and capecitabine, TPX induction chemotherapy, docetaxel, nedaplatin, and fluorouracil, TNF induction chemotherapy

Sun Yat-sen University, Tongji Hospital, Wuhan Union Hospital, China, Peking University, Air Force Military Medical University, China, Second Affiliated Hospital of Soochow University, The First Affiliated Hospital of Guangdong Pharmaceutical University, First People's Hospital of Foshan, Fifth Affiliated Hospital, Sun Yat-Sen University, Cancer Hospital of Guizhou Province, Xiangya Hospital of Central South University, Jilin Provincial Tumor Hospital, Henan Cancer Hospital, Hunan Cancer Hospital, Cancer Hospital of Guangxi Medical University, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Zhejiang Cancer Hospital

Nasopharyngeal Carcinoma

06/24

06/26

CONnECT, NCT05063994 / 2021-003668-29: Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

Completed

Europe, Japan, US

Chronocort, Hydrocortisone modified-release, Cortef, Immediate-release hydrocortisone, IRHC, Placebo

Neurocrine UK Limited, Diurnal Limited

Congenital Adrenal Hyperplasia

02/24

NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

Recruiting

Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol

Planned Parenthood League of Massachusetts

Abortion

07/24

09/24

HERTHENA-Lung02, NCT05338970 / 2021-005879-40: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting

586

Europe, Canada, Japan, US, RoW

Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy

Daiichi Sankyo, Merck Sharp & Dohme LLC

Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

05/24

06/26

CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting

102

Europe, Canada, US, RoW

Ampreloxetine, TD-9855, Placebo

Theravance Biopharma

Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy

12/24

01/27

NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Recruiting

1500

Transdermal system containing progestin

Mylan Pharmaceuticals Inc

Female Contraception

03/27

04/27

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Heinemann, Volker

FIRE-4, NCT02934529 / 2014-003787-21: Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Completed

673

Europe

Irinotecan, Campto, Folinic Acid, Folgamma mono, 5-FU, Fluorouracil, Cetuximab, Erbitux, Bevacizumab, Avastin, Capecitabine, Xeloda, regorafenib, CAS #:755037-03-7, Irinotecan 125mg, Cetuximab wkly

Ludwig-Maximilians - University of Munich

Metastatic Colorectal Cancer

01/25

RAMTAS, NCT03520946 / 2017-004162-99: RAMucirumab in Combination Wth TAS102 vs. TAS102 Alone in Chemotherapy Refractory Metastatic Colorectal Cancer Patients

Completed

430

Europe

Ramucirumab, TAS 102

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Eli Lilly and Company, Trium Analysis Online GmbH

Colorectal Cancer

07/24

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Colorectal Neoplasms

04/26

07/29

FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting

200

Europe, US, RoW

Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice

TransThera Sciences (Nanjing), Inc.

Cholangiocarcinoma

05/26

08/26

AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

FOOTPATH, NCT03487016: First-line Therapy in Metastatic PDAC

Active, not recruiting

270

Europe

Gemcitabine, Gemzar, Nab-paclitaxel, Abraxane, 5-FU, 5-Fluoruracil, Irinotecan Liposomal Injection, Onivyde, Oxaliplatin, Trans-l-diaminocyclohexanoxalatoplatin

Ludwig-Maximilians - University of Munich

Metastatic Pancreatic Cancer

07/22

07/23

FIRE-4.5, NCT04034459: FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC

Active, not recruiting

109

Europe

Bevacizumab, Irinotecan, Folinic acid, Oxaliplatin, 5-FU, Cetuximab

Ludwig-Maximilians - University of Munich

Metastatic Colorectal Cancer

11/23

12/23

NCT03530267: Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Met. Colorectal Cancer

Completed

124

Europe

Aflibercept + mLV5FU2, mFOLFOX7

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, STABIL - Statistische und Biometrische Lösungen, Trium Analysis Online GmbH, Sanofi

Colorectal Cancer

02/24

NCT04034173: Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Not yet recruiting

120

Europe

Panitumumab, Irinotecan, Folinic acid, 5-FU

Ludwig-Maximilians - University of Munich, Amgen, ClinAssess GmbH

Treatment Related Cancer

08/24

08/26

AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting

154

Europe, Canada, Japan, US, RoW

Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A

GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd

Neoplasms, Rectal

11/26

10/29

C-PRECISE-01, NCT04495621 / 2019-003727-38: MEN1611 With Cetuximab in Metastatic Colorectal Cancer

Completed

1/2

Europe, US

MEN1611, Cetuximab

Menarini Group, Menarini Ricerche S.p.A.

Metastatic Colorectal Cancer

01/24

02/24

TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting

N/A

500

Europe, RoW

Data collection and quality of life questionnaire

Centre Leon Berard

06/25

FIRE-7, NCT04852250: Centralized Tumour Board and Secondary Intervention Rate in mCRC

Not yet recruiting

N/A

130

Virtual centralized multidisciplinary tumour board

Ludwig-Maximilians - University of Munich, Charité Universitätsmedizin, Department of Hematology, Oncology and Tumor Immunology

Metastatic Colorectal Cancer, RAS Mutation, Multidisciplinary Communication, Secondary Intervention

03/23

03/25

Ryoo, Baek-Yeol

ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting

2/3

600

Europe, US, RoW

SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo

Panbela Therapeutics, Inc.

Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV

08/26

01/27

Petronio, Anna S

GIOTTO, NCT03521921: GIse Registry Of Transcatheter Treatment of Mitral Valve regurgitaTiOn

Active, not recruiting

N/A

1500

Europe

Mitraclip

IRCCS Policlinico S. Donato

Mitral Regurgitation

02/21

09/25

AHEAD, NCT03339115: European Feasibility Study of the Cardiovalve Transfemoral Mitral Valve System

Recruiting

N/A

Europe

Cardiovalve Transfemoral Mitral Valve

Cardiovalve Ltd., Meditrial Europe Ltd., Meditrial SrL

Mitral Regurgitation, Mitral Valve Disease

12/24

12/29

NCT04817735: The CASPER Registry

Completed

N/A

100

Europe

TAVI

University of Pisa

Bicuspid Aortic Valve

12/24

RESOLVE-MR, NCT04818502: Real World Study of the Tendyne™ Mitral Valve System to Treat Mitral Regurgitation

Active, not recruiting

N/A

200

Europe, RoW

Tendyne™ Mitral Valve System, Transcatheter Mitral Valve Implantation (TMVI)

Abbott Medical Devices

Mitral Valve Regurgitation

05/25

05/29

TENDER, NCT04898335: Tendyne European Experience Registry

Recruiting

N/A

400

Europe

Tendyne Mitral Valve System

Klinikum der Universitaet Muenchen

Mitral Regurgitation

12/26

12/27

Caterina, Raffaele De

RISE-HF, NCT06270498: Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure

Recruiting

Europe

Sucrosomial iron, SiderAL Forte, Placebo

Raffaele De Caterina, University of Pisa, Italy

Chronic Heart Failure, Iron-deficiency, Left Ventricular Systolic Dysfunction

03/25

06/25

CAMP, NCT04679727: The Carotid Artery Multi-modality Imaging Prognostic () Study

Recruiting

N/A

200

Europe

Carotid Artery Diseases, Carotid Artery Plaque, Carotid Atherosclerosis

07/23

07/24

BORG, Christophe

Active, not recruiting

920

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

05/25

05/26

PHARBEVACOL, NCT06642844: Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Not yet recruiting

244

Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group

Unresectable Metastatic Colorectal Cancer

10/28

10/29

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Colorectal Neoplasms

04/26

07/29

SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting

800

Europe

Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine

Biliary Tract Neoplasms

06/27

06/28

REPROGRAM-02, NCT05462613: Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer

Recruiting

2/3

446

Europe

quality of life questionnaires, Blood sample, Regorafenib, Metronomic chemotherapies, Aspirin, Bevacizumab, FOLFIRI or FOLFOX

Centre Hospitalier Universitaire de Besancon

Metastatic Colorectal Cancer

11/29

11/30

APACaPOp, NCT03400072: Adapted Physical Activity in Patients With Resected Pancreatic Cancer ( PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial

Recruiting

252

Europe

Unsupervised APA program, Supervised APA program

Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group

Pancreas Cancer, Quality of Life

02/22

08/24

IMMUNO-BIL, NCT03704480: Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.

Active, not recruiting

106

Europe

Durvalumab, MEDI4736, Tremelimumab, CP-675

GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca

Advanced Biliary Tract Carcinoma

07/22

12/24

SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting

Europe

MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil

GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG

Anal Cancer

02/23

12/24

DONEPEZOX, NCT05254639: Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study

Completed

Europe

DONEPEZIL, PLACEBO

University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive

Digestive Oncology, Supportive Care

01/24

MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting

307

Europe

Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan

GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca

Metastatic Pancreatic Adenocarcinoma

07/23

12/24

SPARTANA, NCT04894370: Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma

Recruiting

Europe

Sample collection

Centre Hospitalier Universitaire de Besancon, National Cancer Institute, France, Novartis

Squamous Cell Anal Carcinoma, Metastatic Squamous Cell Carcinoma

06/25

11/26

KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting

352

Europe, Canada, US

tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin

Seagen, a wholly owned subsidiary of Pfizer, Genmab, Merck Sharp & Dohme LLC

Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck

09/25

08/26

CLavSyn, NCT03117972: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels

Terminated

Europe

FOLFOXIRI, Irinotecan, Oxaliplatin, Leucovorin, 5-Fluorouracil, FOLFOX, FOLFIRI, Ironotecan, Bevacizumab, LV5FU2, Capecitabine

Centre Hospitalier Universitaire de Besancon

Metastatic Colorectal Cancer

08/24

11/24

TEDOPAM, NCT03806309: Maintenance With OSE2101 Plus FOLFIRI, or FOLFIRI After FOLFIRINOX-based Induction Therapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting

106

Europe

FOLFIRI, Leucovorin (Folinic Acid), Fluorouracil, Irinotecan, OSE2101, Tedopi

GERCOR - Multidisciplinary Oncology Cooperative Group, OSE Immunotherapeutics

Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer, Metastatic Cancer

12/23

12/24

C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting

234

Europe, US, RoW

Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care

Agenus Inc.

Metastatic Colorectal Cancer

02/25

07/25

ALIX, NCT03974854: Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma

Terminated

Europe

XELOXIRI-3, Capecitabine, Oxaliplatine, Irinotecan, Gemcitabine

Centre Hospitalier Universitaire de Besancon

Metastatic Pancreatic Adenocarcinoma

08/23

02/24

INTERACT-ION, NCT04719988: Anti-PD-1 and mDCF Followed by Chemoradiotherapy in Patients With Stage III Squamous Cell Anal Carcinoma.

Active, not recruiting

Europe

Blood sample collection, Biopsy

Centre Hospitalier Universitaire de Besancon, Boehringer Ingelheim

Squamous Cell Carcinoma of the Anus Stage III

11/24

07/26

CARE, NCT06425133: Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers

Recruiting

174

Europe

Blood sample, Quality of life questionnaires, Biopsy, Regorafenib, Regorafenib + metronomic chemotherapy

Centre Hospitalier Universitaire de Besancon, Groupement Interrégional de Recherche Clinique et d'Innovation

Metastatic Colorectal Cancer

09/27

09/28

VolATIL, NCT03946358: Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers

Completed

Europe

Blood sample collection, Tumor biopsies, CT scan, Atezolizumab, anti-PD-L1, UCPVax, Vaccine

Centre Hospitalier Universitaire de Besancon, Roche Pharma AG, National Cancer Institute, France

Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer

03/24

11/24

REGINA, NCT04503694 / 2020-000876-40: Neoadjuvant Regorafenib in Combination with Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer

Recruiting

Europe

Nivolumab 10 MG/ML Intravenous Solution, Regorafenib 30 MG Oral Tablet, Radiotherapy, Surgery, Non-operative Management

Jules Bordet Institute

Rectal Cancer Stage II, Rectal Cancer Stage III

01/26

12/30

FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Recruiting

400

Europe

FOLFOX regimen, CAPOX regimen

UNICANCER

Digestive Cancer, Colorectal Cancer

04/27

01/30

TRIFLUOX-DP, NCT06245356: Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Not yet recruiting

Europe

Lonsurf, Oxaliplatin, Panitumumab, Bevacizumab, Trastuzumab, Nivolumab

UNICANCER, Servier

Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency

10/26

10/28

TERTIO, NCT05528952: Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Recruiting

105

Europe

Atezolizumab, Bevacizumab, UCPVax

Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group, PRODIGE

Hepatocellular Carcinoma

04/25

09/27

Recruiting

118

Europe

Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO

UNICANCER, Servier

Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

01/26

01/27

NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting

Europe

Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen

Inspirna, Inc.

Colorectal Cancer, Metastatic Colon Cancer

01/25

03/25

AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting

154

Europe, Canada, Japan, US, RoW

Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A

GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd

Neoplasms, Rectal

11/26

10/29

NIPISAFE, NCT04730544 / 2020-004366-19: Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

Active, not recruiting

Europe

Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab

GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb

Colorectal Cancer Metastatic, MSI-H Colorectal Cancer

04/27

04/28

Recruiting

1/2

160

Europe

trifluridine/tipiracil + XB2001, trifluridine/tipiracil + placebo

Centre Georges Francois Leclerc

Metastatic Colorectal Cancer

10/26

Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active, not recruiting

1/2

374

Europe, Canada, Japan, US, RoW

Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil

Takeda, Takeda Development Center Americas, Inc. (TDC Americas)

Solid Neoplasms

01/26

AUDREY, NCT05589597 / 2022-002805-90: EO4010 in Previously Treated Metastatic Colorectal Carcinoma

Active, not recruiting

1/2

Europe, US

EO4010, Nivolumab, Bevacizumab

Enterome, Enterome SA

Colorectal Cancer Metastatic

02/26

Epitopes-CRC01, NCT02838381: Study of Genetic and Cellular Immunological Parameters Predictive of Disease-free Survival in Patients With Metastatic Cancer

Completed

N/A

553

Europe

Additional biological samples

Centre Hospitalier Universitaire de Besancon

Metastatic Cancer

12/23

06/24

PREDICT-IRFC, NCT04767568: Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening

Recruiting

N/A

400

Europe

Blood sample, Tumor tissue, stool collection

Centre Hospitalier Universitaire de Besancon

Colorectal Cancer

08/25

09/28

Pancreas-CGE, NCT02818907: Evaluation of Survival Prognostic Factors for Patients With Exocrine Pancreatic Cancer Resectable or Potentially Resectable

Completed

N/A

290

Europe

Additional biological samples

Centre Hospitalier Universitaire de Besancon, Cancéropôle Grand-Est

Pancreatic Cancer

07/23

NCT06515821: Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods

Recruiting

N/A

4100

Europe, RoW

ONCOSCREEN

Firalis SA, University Medical Center Mainz

Colorectal Cancer

12/26

HORIZON, NCT06626269: Identification of Innovative Biomarkers Related to the Immune System or Tumor Microenvironment to Promote the Efficacy of Immunotherapies

Not yet recruiting

N/A

700

Europe

Blood sample, Tumor tissue

Centre Hospitalier Universitaire de Besancon

Advanced Digestive Cancer, Advanced Gynecologic Cancer

01/30

01/32

CLIMES, NCT05787197: ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

Recruiting

N/A

232

Europe

GERCOR - Multidisciplinary Oncology Cooperative Group

Metastatic Colorectal Cancer, Circulating Tumor DNA

09/25

06/27

CIRCA-HPV, NCT03739775: Circulating Tumor DNA for the Early Detection of HPV-positive Pelvic Cancer Relapses

Recruiting

N/A

172

Europe

Blood sampling

Institut Curie

HPV Positive Pelvic Cancer

06/26

SMITH, Denis

Recruiting

250

Europe, US, RoW

ITM Solucin GmbH

Neuroendocrine Tumors

06/27

09/27

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC

Colorectal Neoplasms

04/26

07/29

Recruiting

348

Europe

Federation Francophone de Cancerologie Digestive

Colorectal Neoplasms

09/25

09/27

AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting

711

Europe, Canada, Japan, US, RoW

Dostarlimab, CAPEOX, FOLFOX

GlaxoSmithKline

Colonic Neoplasms, Neoplasms, Colon

12/28

12/30

SCARCE, NCT03519295 / 2017-003185-27: A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

Active, not recruiting

Europe

MPDL3280A, atezolizumab, mDCF, modified docetaxel, cisplatin, and fluorouracil

GERCOR - Multidisciplinary Oncology Cooperative Group, Roche Pharma AG

Anal Cancer

02/23

12/24

DONEPEZOX, NCT05254639: Donepezil for Oxaliplatin-induced Neuropathy Peripheral Neuropathy: Proof of Concept Study

Completed

Europe

DONEPEZIL, PLACEBO

University Hospital, Clermont-Ferrand, Federation Francophone de Cancerologie Digestive

Digestive Oncology, Supportive Care

01/24

NCT04579679 / 2020-006118-19: Open-Label Surufatinib in European Patients with NET

Completed

Europe, US

Surufatinib, HMPL-012, sulfatinib

Hutchmed

Neuroendocrine Tumours, Neuroendocrine Tumour of the Lung, Small Intestinal NET

10/24

IMMUNOGAST, NCT04739202 / 2020-000297-17: Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma

Recruiting

Europe

Atezolizumab + Ipatasertib, Atezolizumab + Bevacizumab

Hospices Civils de Lyon, Roche, Inca

Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma, Advanced Gastric Carcinoma

10/23

LONGBOARD, NCT04166604: LONsurf and G-CSF Use: Being On A Right Dose-intensity to Optimize Treatment Efficacy

Active, not recruiting

176

Europe

Trifluridine/Tipiracil, Lonsurf

GERCOR - Multidisciplinary Oncology Cooperative Group

Metastatic Colorectal Cancer

11/23

11/24

Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI

Recruiting

120

Europe

Dostarlimab, Chemotherapy

UNICANCER, National Cancer Institute, France, GlaxoSmithKline

10/28

09/30

POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting

Europe

Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab

Federation Francophone de Cancerologie Digestive

Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable

09/24

SOREGATT, NCT04450836 / 2019-004196-39: Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

Terminated

234

Europe

Regorafenib then Trifluridine/Tipiracil, STIVARGA, LONSURF, Trifluridine/Tipiracil then Regorafenib

UNICANCER, Bayer HealthCare Pharmaceuticals Inc.

Metastatic Colorectal Cancer

03/24

12/24

FUDOSE, NCT06475352: Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

Recruiting

400

Europe

FOLFOX regimen, CAPOX regimen

UNICANCER

Digestive Cancer, Colorectal Cancer

04/27

01/30

AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Active, not recruiting

154

Europe, Canada, Japan, US, RoW

Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A

GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd

Neoplasms, Rectal

11/26

10/29

NIPISAFE, NCT04730544 / 2020-004366-19: Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

Active, not recruiting

Europe

Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab

GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb

Colorectal Cancer Metastatic, MSI-H Colorectal Cancer

04/27

04/28

BETTER 2, NCT03351296 / 2017-000741-46: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting

140

Europe

LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab

Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France

Pancreatic Cancer

12/28

NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting

Europe

Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment

GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD

Neuroendocrine Carcinoma, Digestive Cancer

01/34

06/34

CLIMES, NCT05787197: ctDNA in CRC Patients Undergoing Curative-intent Surgery for Liver Metastases

Recruiting

N/A

232

Europe

GERCOR - Multidisciplinary Oncology Cooperative Group

Metastatic Colorectal Cancer, Circulating Tumor DNA

09/25

06/27

Petrini, Mario

TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

May 2019 - Dec 2023 : Regulatory submission in EU for front line maintenance MCL

Recruiting

870

Europe

R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)

Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum

Mantle Cell Lymphoma

05/21

05/26

GITMO-PHYLOS, NCT03270748: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

Completed

Europe

GvHD prophylaxis

Gruppo Italiano Trapianto di Midollo Osseo

Myeloid Malignancies

11/22

NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Active, not recruiting

Europe

Ibrutinib, IMBRUVICA (commercial name)

Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A.

DLBCL

07/24

07/27

FIL_Copa-RB, NCT04433182 / 2019-004898-63: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma

Terminated

Europe

Copanlisib, ALIQOPA

Fondazione Italiana Linfomi - ETS

Diffuse Large B-cell Lymphoma

12/24

Simoncini, Tommaso

NCT04209543 / 2019-001289-14: Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Completed

1570

Europe, Canada, US, RoW

Estetrol, Placebo, Progesterone

Estetra, ICON Clinical Research

Vasomotor Symptoms, Menopausal Symptoms

02/24

MoMM-FET, NCT06288126: Maternal and Fetal Metabolic Changes

Completed

N/A

457

Europe

Azienda Ospedaliero, Universitaria Pisana

Pregnancy Related, Maternal-Fetal Relations, Metabolism Disorder, Glucose

10/20

01/21

MATERNALLY, NCT06852703: Predictive BioMArkers of AlTERed NeurologicAL Trajectories Consequent to PrenataL InflammatorY Insults

Recruiting

N/A

300

Europe

Infection during pregnancy

Istituto Clinico Humanitas, IRCCS Fondazione Stella Maris, Azienda Ospedaliero, Universitaria Pisana

Biomarkers, Neurodevelopmental Disorders, Inflammation, Brain

04/24

08/25

Investigator, Principal

OCEAN, NCT04986982 / 2020-001175-32: OpiCapone Effect on Motor Fluctuations and pAiN

Completed

144

Europe

Opicapone 50 mg, BIA 9-1067, Placebo

Bial - Portela C S.A., Bial - Portela & Ca, S.A.

Parkinson Disease

02/24

NCT04248205: Ketamine for Post-operative Analgesia in Hemorrhoidectomy

Recruiting

100

Ketamine

University of Oklahoma

Hemorrhoids

01/25

07/25

NCT05400369: A Study to Evaluate the Efficacy and Safety of Sitafloxacin in Adult Subjects With Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Completed

140

RoW

Sitafloxacin, Gracevit, Moxifloxacin Hydrochloride, Avelox

Daiichi Sankyo

COPD Exacerbation Acute

09/24

TrEAT_TD2, NCT05677282: Single Dose Antibiotic Treatment of Acute Watery Diarrhea, Rifaximin Versus Azithromycin, with Loperamide Adjunct

Recruiting

150

RoW

Rifaximin 550 MG, Azithromycin 500 MG, Loperamide

Henry M. Jackson Foundation for the Advancement of Military Medicine, Infectious Diseases Clinical Research Program, Uniformed Services University of the Health Sciences

Diarrhoea;Acute, Diarrhea Travelers

09/25

12/25

NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy

Recruiting

TARPEYO®, delayed-release budesonide capsules

Calliditas Therapeutics AB, Worldwide Clinical Trials

IgA Nephropathy

05/26

11/27

NCT06793358: Use of Remimazolam and Fentanyl for Procedural Sedation in Patients Undergoing Dental Extraction

Not yet recruiting

fentanyl and Remimazolam

Indiana University, Indiana University Health

Dental Extraction

03/26

POUR, NCT04994431: Post-Operative Urinary Retention () in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Terminated

109

Tamsulosin Hydrochloride

University of Massachusetts, Worcester, UMass Memorial Health Care

Thoracic Diseases, Urinary Retention

10/23

NCT06397781: Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients

Not yet recruiting

100

Skin Cleanser Combination No.1

Boston Children's Hospital

Atopic Dermatitis

12/28

NCT02932410 / 2016-001062-28: A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)

Active, not recruiting

165

Europe, Canada, US, RoW

Macitentan, ACT-064992, Standard-of-care

Actelion

Pulmonary Arterial Hypertension

08/24

11/25

TROPION-LUNG01, NCT04656652 / 2020-004643-80: Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations

	Oct 2024 - Mar 2025 : Regulatory decision in US for 2L+ NSCLC
	Jul 2023 - Dec 2023 : Acceptance of regulatory submission for 2L+ NSCLC with or without actionable genomic alterations (based on TROPION-Lung01 trial)
	Apr 2023 - Jun 2023: Topline results from TROPION-LUNG01 trial for metastatic NSCLC

Active, not recruiting

590

Europe, Canada, Japan, US, RoW

DS-1062a, Datopotamab deruxtecan (Dato-DXd), Docetaxel

Daiichi Sankyo, AstraZeneca

Non-small Cell Lung Cancer

05/24

01/26

IDeate-Lung02, NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting

540

Europe, Canada, Japan, US, RoW

Ifinatamab deruxtecan, I-DXd, Topotecan, Amrubicin, Lurbinectedin

Daiichi Sankyo, Merck Sharp & Dohme LLC

Small Cell Lung Cancer

04/27

02/29

TNX-N, NCT03503136: Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in IC + CCRT for Locoregionally Advanced NPC

Not yet recruiting

632

RoW

Nasopharyngeal Carcinoma

06/24

06/26

CONnECT, NCT05063994 / 2021-003668-29: Comparison of Chronocort Versus Standard Hydrocortisone Replacement Therapy in Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

Completed

Europe, Japan, US

Chronocort, Hydrocortisone modified-release, Cortef, Immediate-release hydrocortisone, IRHC, Placebo

Neurocrine UK Limited, Diurnal Limited

Congenital Adrenal Hyperplasia

02/24

NCT05839899: Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location

Recruiting

Mifepristone plus one dose Misoprostol, Mifepristone plus two doses Misoprostol

Planned Parenthood League of Massachusetts

Abortion

07/24

09/24

HERTHENA-Lung02, NCT05338970 / 2021-005879-40: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Active, not recruiting

586

Europe, Canada, Japan, US, RoW

Patritumab Deruxtecan, HER3-DXd, U3-1402, Platinum-based chemotherapy

Daiichi Sankyo, Merck Sharp & Dohme LLC

Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion

05/24

06/26

CYPRESS, NCT05696717: Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy

Recruiting

102

Europe, Canada, US, RoW

Ampreloxetine, TD-9855, Placebo

Theravance Biopharma

Symptomatic Neurogenic Orthostatic Hypotension, MSA - Multiple System Atrophy

12/24

01/27

NCT06672016: Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential

Recruiting

1500

Transdermal system containing progestin

Mylan Pharmaceuticals Inc

Female Contraception

03/27

04/27

12 3 4 5 6 7 8 9 10 11 12 13...14 15 »

Download Options



	Diseases Companies Products Productz Mechanisms of Action Sites